These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12849615)

  • 1. Anti-HER2 therapy: how to use Herceptin in clinical practice.
    Böhme C
    Eur J Oncol Nurs; 2000 Mar; 4(Sa):30-6. PubMed ID: 12849615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
    Smith IE
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
    Cook-Bruns N
    Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line Herceptin monotherapy in metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
    Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herceptin: implications for breast cancer management.
    Kearney N; McPhail G
    Eur J Oncol Nurs; 2000 Mar; 4(Sa):37-41. PubMed ID: 12849616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can we learn from Herceptin trials in metastatic breast cancer?
    Bell R
    Oncology; 2002; 63 Suppl 1():39-46. PubMed ID: 12422054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trials of new combinations of Herceptin in metastatic breast cancer.
    Thomssen C
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S19-25. PubMed ID: 11989523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herceptin: increasing survival in metastatic breast cancer.
    Slamon D
    Eur J Oncol Nurs; 2000 Mar; 4(Sa):24-9. PubMed ID: 12849614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herceptin: the future in adjuvant breast cancer therapy.
    Piccart-Gebhart MJ
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S27-33. PubMed ID: 11989524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving forward: Herceptin in the adjuvant setting.
    Tan-Chiu E; Piccart M
    Oncology; 2002; 63 Suppl 1():57-63. PubMed ID: 12422056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.
    Miles DW
    Breast Cancer Res; 2001; 3(6):380-4. PubMed ID: 11737889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of single-agent trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model.
    Colbern GT; Hiller AJ; Musterer RS; Working PK; Henderson IC
    J Inorg Biochem; 1999 Oct; 77(1-2):117-20. PubMed ID: 10626363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.